- PerkinElmer Announces New Collaboration with the National Center for Drug Screening to Advanced Personalized Medicine and Drug Profiling in China
Product News: PerkinElmer Announces New Collaboration with the National Center for Drug Screening to Advanced Personalized Medicine and Drug Profiling in ChinaPerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced a new collaboration with the National Center for Drug Screening (NCDS) to advance personalized medicine and drug profiling in China. Through sharing knowledge, expertise and innovative capabilities, the two organizations will establish a personalized drug research and development platform that will validate biomarkers for individualized disease treatment for Chinese patients.
Special guests including key governmental leaders, Mr. Jianjun Cheng, CCP Secretary of Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Mr. Weihua Song, Deputy Director of Shanghai Zhangjiang INNOPARK Administrative Committee; Mr. Robert Friel, PerkinElmer's Chairman and Chief Executive Officer; and Dr. Ming-Wei Wang, Director of NCDS among others, participated in a ceremony today celebrating the collaboration at the Chinese National Compound Library in Zhangjiang Hi-tech Park, Shanghai.
"It is an honor for PerkinElmer to collaborate with Dr. Wang, who is one of the pioneers in the field of personalized medicine," Mr. Friel said. "We look forward to working with Dr. Wang, the National Center for Drug Screening and Chinese scientists to develop a significant personalized drug research and development technology platform which will enable patients to be treated more accurately, safely, and efficiently."
The program will include sequencing patient samples in order to establish genomic information for drug profiling, including validation of biomarkers for personalized disease treatment and related informatics solutions. As a part of this program, PerkinElmer and NCDS will first undertake a study on metabolic diseases to validate new diagnostics for the Chinese populations through utilizing next generation sequencing technologies. Once optimized, the technology platform will be implemented in testing laboratories and hospitals throughout China.
"As an important customer and long-term collaborator of PerkinElmer in the field of life sciences and drug discovery, the National Center for Drug Screening is committed to the research and development of new and effective drugs," Dr. Ming-Wei Wang said, "For the majority of drugs that are available in China, the respective biomarkers have not yet been fully validated. We are very excited to build this state-of-the-art personalized medicine program with PerkinElmer which will allow us to offer vital insights to improve the quality of healthcare in China."